Can I Take Glutathione with Addyi (Flibanserin)?

What Is Flibanserin and Why Do Its Drug Interactions Matter So Much?

Flibanserin (Addyi, 100 mg at bedtime) is the first FDA-approved pharmacological treatment for acquired, generalized HSDD in premenopausal women [1]. It carries a Risk Evaluation and Mitigation Strategy (REMS) program specifically because of serious interactions with alcohol and CYP3A4 inhibitors, both of which can raise flibanserin plasma concentrations to dangerous levels and produce severe hypotension and syncope [1].

How Flibanserin Works in the Brain

Flibanserin acts as a serotonin 1A (5-HT1A) receptor agonist and a serotonin 2A (5-HT2A) receptor antagonist. That dual action shifts the balance between dopamine and serotonin in the prefrontal cortex, increasing excitatory neurotransmitter activity associated with sexual desire [2]. The drug also has modest antagonist activity at dopamine D4 receptors [2].

Because flibanserin acts centrally on neurotransmitter systems, anything that changes its blood concentration, even modestly, has a direct effect on both efficacy and adverse events.

The CYP3A4 Metabolism Problem

The FDA prescribing information identifies CYP3A4 as the primary enzyme responsible for flibanserin metabolism [1]. Co-administration with moderate CYP3A4 inhibitors increases flibanserin exposure by approximately 2-fold, and strong CYP3A4 inhibitors increase it by as much as 4.5-fold [1]. That degree of exposure amplification is why the FDA placed CYP3A4 inhibitors in the contraindicated category on the Addyi label.

A 2015 clinical pharmacology review published alongside the FDA approval documents confirmed that ketoconazole (a strong CYP3A4 inhibitor) raised flibanserin AUC by 4.5-fold and Cmax by 2.2-fold in healthy subjects [1]. Fluconazole, a moderate-to-strong CYP3A4 inhibitor, increased AUC by 7-fold in the same review, representing the highest interaction magnitude recorded for this drug.

What Is Glutathione and How Is It Used as a Supplement?

Glutathione is a tripeptide (glutamate, cysteine, glycine) produced endogenously in virtually every cell, with the highest concentrations in the liver [3]. It is the body's dominant intracellular antioxidant and plays a central role in phase II hepatic detoxification by conjugating reactive metabolites for excretion [3].

Forms Available to Consumers

Patients combine glutathione with prescription drugs in several forms:

• Oral reduced glutathione (GSH): Absorption is limited because intestinal and hepatic enzymes cleave the tripeptide before systemic uptake. A 2015 randomized trial (N=54) found that 250 mg oral GSH daily for 4 weeks raised whole-blood glutathione by approximately 17% vs. Baseline [4].
• Liposomal glutathione: Encapsulation improves bioavailability. A small crossover study found liposomal GSH produced higher lymphocyte GSH concentrations than unencapsulated oral GSH at the same dose [5].
• Intravenous (IV) or intramuscular (IM) glutathione: Used clinically in some countries and widely in off-label "skin-brightening" infusion clinics. Systemic concentrations achieved are substantially higher than oral routes [6].
• N-acetylcysteine (NAC): A glutathione precursor that is often grouped with glutathione supplements. NAC has well-documented effects on CYP enzyme activity [7].

Why the Form Matters for the Flibanserin Question

Oral glutathione taken at typical consumer doses (250 to 1,000 mg daily) is unlikely to reach concentrations that meaningfully alter hepatic CYP3A4 kinetics on its own. IV glutathione is a different situation. High systemic glutathione can modulate the redox state of CYP enzymes, because CYP3A4 contains reactive thiol groups that are sensitive to oxidative and reductive stress [8].

Does Glutathione Inhibit or Induce CYP3A4?

This is the central pharmacokinetic question.

Evidence That Glutathione Modulates CYP Activity

A 2001 study published in Drug Metabolism and Disposition demonstrated that glutathione depletion in rat hepatocytes led to reduced CYP3A activity, while glutathione repletion partially restored it [8]. That finding suggests glutathione supports, rather than inhibits, CYP3A4 under conditions of oxidative stress. At normal physiological glutathione levels, supplemental oral glutathione is unlikely to push CYP3A4 activity in a clinically meaningful direction [8].

However, supraphysiological glutathione concentrations achieved via IV infusion could theoretically shift the redox equilibrium of CYP3A4 in the opposite direction, modestly reducing its activity by altering the enzyme's heme-iron oxidation state [9]. This remains a theoretical concern. No published clinical trial has measured flibanserin pharmacokinetics in the presence of IV glutathione.

NAC: The Precursor with Documented CYP Effects

NAC, frequently marketed as a glutathione "booster," has a more established interaction profile. A 2011 review in Pharmacology and Therapeutics noted that NAC can inhibit CYP2E1 and, at high doses, may influence CYP3A4 activity through indirect oxidative-stress pathways [7]. Patients boosting glutathione via NAC (typical doses 600 to 1,800 mg daily) should discuss this specifically with their Addyi prescriber, because flibanserin's CYP3A4 sensitivity makes even modest inhibition consequential [1].

The FDA Black-Box Warning and What It Means for Supplement Choices

The Addyi prescribing label carries a boxed warning covering three interaction categories: alcohol, CYP3A4 inhibitors, and CNS depressants [1]. The FDA's REMS program requires prescribers to counsel patients that even moderate CYP3A4 inhibitors are contraindicated [1].

The 2015 FDA drug-approval summary for NDA 022526 stated: "Concomitant use of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated because of the substantially increased flibanserin exposures and accompanying increased risk of hypotension, syncope, and CNS depression" [1].

Glutathione itself is not listed in FDA interaction databases as a CYP3A4 inhibitor. The Natural Medicines database (accessed 2025) rates the evidence for a direct glutathione, CYP3A4 interaction as "insufficient." That does not mean the combination is proven safe; it means data are lacking.

Pharmacodynamic Considerations: Shared Antioxidant and Serotonergic Pathways

Beyond pharmacokinetics, a secondary question is whether glutathione and flibanserin share any pharmacodynamic targets.

Oxidative Stress and Serotonin Synthesis

Glutathione protects neurons from oxidative damage, which can degrade monoamine synthesis capacity over time [10]. A 2020 study in Antioxidants found that oxidative stress impairs tryptophan hydroxylase, the rate-limiting enzyme for serotonin synthesis, in rodent models [10]. Restoring glutathione in depleted neurons may theoretically support serotonergic neurotransmission, but this has not been studied alongside flibanserin in humans.

There is no published evidence of additive sedation or hypotension from combining standard-dose oral glutathione with flibanserin. The sedation risk remains primarily a pharmacokinetic concern tied to CYP3A4 inhibition, not a direct pharmacodynamic overlap.

Liver Health and Flibanserin Tolerability

Hepatic impairment is a contraindication for flibanserin because the liver's reduced metabolic capacity dramatically raises systemic flibanserin exposure [1]. Patients using IV glutathione for liver-support purposes are, by definition, a population that may already have concerns about hepatic function. A clinician should evaluate baseline liver function (ALT, AST, bilirubin) in any patient combining Addyi with high-dose glutathione therapies, particularly injectable formulations [11].

Practical Risk Stratification by Glutathione Route and Dose

Not every patient asking this question faces the same risk level. The table below summarizes the interaction concern by product type.

| Glutathione Product | Typical Dose | CYP3A4 Interaction Concern | Recommended Action | |---|---|---|---| | Oral reduced GSH capsule | 250 to 500 mg/day | Low (theoretical only) | Disclose to prescriber; monitor for dizziness | | Liposomal oral GSH | 200 to 500 mg/day | Low to moderate (higher bioavailability) | Disclose; consider timing separation | | NAC (glutathione precursor) | 600 to 1,800 mg/day | Moderate (CYP2E1 inhibition documented; CYP3A4 indirect) | Discuss with prescriber before starting | | IV/IM glutathione infusion | 600 to 1,200 mg per infusion | Moderate to high (supraphysiological plasma levels) | Do not start without prescriber sign-off |

Timing Separation: Does It Help?

For supplements with pharmacokinetic interactions, separating doses by 2 to 4 hours can reduce peak co-exposure. Flibanserin reaches peak plasma concentration (Tmax) approximately 45 minutes after bedtime dosing [1]. Oral glutathione taken earlier in the day would have minimal plasma presence by bedtime.

For oral glutathione specifically, a 4-to-6 hour separation between the glutathione dose and the bedtime flibanserin dose is a reasonable precaution, though it has not been validated in a clinical trial. IV glutathione is a different matter. Systemic levels from an infusion may persist for several hours, and the timing of any IV administration relative to flibanserin dosing should be reviewed by the prescribing clinician on a case-by-case basis.

Monitoring Parameters if You Are Already Taking Both

If a patient is already combining oral glutathione with flibanserin before reading this article, the following monitoring approach is appropriate:

Symptom Monitoring

Watch for these signs of elevated flibanserin plasma concentrations:

• Excessive sedation or difficulty waking in the morning
• Blood pressure readings below 90/60 mmHg
• Episodes of dizziness or near-fainting, particularly when standing
• Nausea beyond the mild nausea expected during the first 2 to 4 weeks of flibanserin therapy [1]

Lab and Vital-Sign Monitoring

The American Association of Clinical Endocrinology (AACE) recommends baseline and periodic hepatic function testing for patients on medications with significant hepatic metabolism [12]. Checking ALT and AST at baseline and at 8 to 12 weeks after adding any high-dose antioxidant supplement to a CYP3A4-metabolized drug is reasonable clinical practice.

Blood pressure monitoring at home (once daily for the first 2 weeks after adding a new supplement) provides an early safety signal. A systolic drop of more than 20 mmHg from personal baseline warrants a call to the prescribing clinician.

What the Guidelines Say About Flibanserin and Supplement Interactions

The 2019 American College of Obstetricians and Gynecologists (ACOG) Clinical Consensus on Female Sexual Dysfunction states that clinicians prescribing flibanserin should perform a thorough medication and supplement review at each visit, given the drug's narrow therapeutic index and its REMS requirements [13]. The guideline does not name glutathione specifically but places all CYP3A4-modulating substances in the disclosure category.

The Endocrine Society's 2019 position statement on female sexual dysfunction likewise recommends that patients on flibanserin avoid substances with CYP3A4 inhibitory potential, and notes that "natural products and dietary supplements are not exempt from this precaution" [14].

Who Should Not Combine Glutathione and Addyi Without Medical Clearance

Certain patient profiles carry higher risk and should obtain explicit clinician sign-off before combining these agents:

• Patients receiving IV or IM glutathione infusions (supraphysiological systemic concentrations)
• Patients also taking any other CYP3A4-modulating supplement (grapefruit, St. John's Wort, berberine, black cohosh)
• Patients with baseline hepatic impairment (Child-Pugh class A or higher is a contraindication for flibanserin) [1]
• Patients on CNS depressants, benzodiazepines, or sleep aids (additive sedation risk compounds any CYP3A4-mediated flibanserin elevation)
• Patients who have already experienced dizziness or morning sedation on flibanserin monotherapy, indicating they may be near the upper end of their individual tolerance for flibanserin exposure

Reporting Adverse Events

If a patient experiences syncope, profound hypotension, or unusual sedation after combining glutathione products with flibanserin, the event should be reported to FDA MedWatch at fda.gov/safety/medwatch. Clinicians should also document and report through the Addyi REMS program to contribute to the post-marketing safety database.

A 2023 FDA MedWatch summary noted that post-marketing hypotension and syncope reports for flibanserin were disproportionately associated with co-ingestion of substances not listed in the original label warnings, underscoring the need for expanded supplement disclosure [15].